Document Detail


Exposure of infants to budesonide through breast milk of asthmatic mothers.
MedLine Citation:
PMID:  17825891     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Maintenance treatment with inhaled corticosteroids is often required for asthmatic nursing women. Data on the transfer of inhaled corticosteroids from plasma to breast milk and the subsequent exposure of the breast-feeding infant has been unavailable. OBJECTIVE: We sought to assess budesonide concentrations in milk and plasma of asthmatic nursing women receiving maintenance treatment with the Pulmicort Turbuhaler and estimate the exposure of their breast-fed infants. METHODS: Milk and plasma samples were collected up to 8 hours after dosing from 8 mothers receiving budesonide maintenance treatment (200 or 400 microg twice daily). Pharmacokinetic parameters were calculated from budesonide milk and plasma concentrations. Infant exposure was estimated based on average milk budesonide concentrations. A single blood sample was obtained from 5 infants close to expected infant maximum concentration. RESULTS: Budesonide concentrations in milk reflected those in maternal plasma, supporting passive diffusion of budesonide between plasma and milk, and was always lower than that in plasma. The mean milk/plasma ratio was 0.46. The estimated daily infant dose was 0.3% of the daily maternal dose for both dose levels, and the average plasma concentration in infants was estimated to be 1/600th of the concentrations observed in maternal plasma, assuming complete infant oral bioavailability. Budesonide concentrations in infant plasma samples were all less than the limit of quantification. CONCLUSION: Maintenance treatment with inhaled budesonide (200 or 400 microg twice daily) in asthmatic nursing women results in negligible systemic exposure to budesonide in breast-fed infants. CLINICAL IMPLICATIONS: These data support continued use of inhaled budesonide during breast-feeding.
Authors:
Anette Fält; Thomas Bengtsson; Britt-Marie Kennedy; Ann Gyllenberg; Bengt Lindberg; Lars Thorsson; Kerstin Stråndgarden
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-09-07
Journal Detail:
Title:  The Journal of allergy and clinical immunology     Volume:  120     ISSN:  0091-6749     ISO Abbreviation:  J. Allergy Clin. Immunol.     Publication Date:  2007 Oct 
Date Detail:
Created Date:  2007-10-12     Completed Date:  2007-11-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  1275002     Medline TA:  J Allergy Clin Immunol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  798-802     Citation Subset:  AIM; IM    
Affiliation:
Clinical Development, AstraZeneca R&D, Lund, Sweden. anette.falt@astrazeneca.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Inhalation
Adult
Asthma / drug therapy*
Breast Feeding*
Budesonide / administration & dosage,  pharmacokinetics*
Female
Glucocorticoids / pharmacokinetics*
Humans
Infant
Male
Milk, Human / metabolism*
Chemical
Reg. No./Substance:
0/Glucocorticoids; 51333-22-3/Budesonide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Delineating the specificity of an IgE-encoding transcriptome.
Next Document:  Multivariate statistical analysis of large-scale IgE antibody measurements reveals allergen extract ...